Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II

A. Jungwirth, J. Pinski, G. Galvan, G. Halmos, K. Szepeshazi, R. Z. Cai, K. Groot, M. Vadillo-Buenfil, Andrew V Schally

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

The aim of this study was to test the antagonist of LH-RH (Cetrorelix), agonist [D-Trp6]LH-RH (triptorelin) and new bombesin antagonists RC-3940-II and RC-3950-II for their effect on the growth of an androgen-independent prostate cancer cell line, DU-145, xenografted into nude mice. Xenografts were grown in male nude mice, and after 4 weeks, the animals were treated either with saline (control) or with one of the analogues. One group of mice was given a combination of Cetrorelix and RC-3950-II. Treatment was given for 4 weeks. Tumour and body weights, and tumour volumes were measured. At sacrifice, tumours were dissected for histological examination and receptor studies. Serum was collected for measurement of hormone levels. The final tumour volume in control animals injected with saline was 577 ± 155 mm3 and that of animals treated with Cetrorelix only 121.4 ± 45 mm3 (P < 0.01). Bombesin antagonists RC-3940-II and RC-3950-II also significantly reduced DU- 145 tumour volume in nude mice to 84.9 ± 19.9 and 96.8 ± 28 mm3 respectively. Agonist [D-Trp6]LH-RH did not significantly inhibit tumour growth. Serum levels of LH were decreased to 0.08 ± 0.02 ng/ml (P < 0.05) in the Cetrorelix treated group as compared to 1.02 ± 0.1 ng/ml for the controls, and testosterone levels were reduced to castration levels (0.01 ± 0.01 ng/ml). Specific receptors for EGF and LH-RH in DU-145 tumours were significantly downregulated after treatment with Cetrorelix, RC-3940-II and RC-3950-II. Although LH-RH could be a local regulator of growth of prostate cancer, the fall in LH-RH receptors is not fully understood and the inhibitory effects of Cetrorelix and bombesin antagonists on DU-145 tumour growth might be attributed at least in part to a downregulation of EHF receptors. Since Cetrorelix and bombesin antagonists inhibit growth of androgen-independent DU-145 prostate cancers, these compounds could be considered for the therapy of advanced prostate cancer in men, especially after relapse.

Original languageEnglish
Pages (from-to)1141-1148
Number of pages8
JournalEuropean Journal of Cancer Part A
Volume33
Issue number7
DOIs
StatePublished - Jun 1 1997
Externally publishedYes

Fingerprint

Hormone Antagonists
Bombesin
Gonadotropin-Releasing Hormone
Androgens
Prostatic Neoplasms
Tumor Burden
Growth
Nude Mice
Neoplasms
Down-Regulation
Triptorelin Pamoate
LH Receptors
Castration
cetrorelix
Hca(6)-Leu(13)-psi(CH2N)-Tac(14)-bombesin(6-14)
Serum
Heterografts
Testosterone
Body Weight
Hormones

Keywords

  • Androgen-independent prostate cancer
  • Bombesin/GRP antagonists
  • LH-RH antagonist

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. / Jungwirth, A.; Pinski, J.; Galvan, G.; Halmos, G.; Szepeshazi, K.; Cai, R. Z.; Groot, K.; Vadillo-Buenfil, M.; Schally, Andrew V.

In: European Journal of Cancer Part A, Vol. 33, No. 7, 01.06.1997, p. 1141-1148.

Research output: Contribution to journalArticle

Jungwirth, A. ; Pinski, J. ; Galvan, G. ; Halmos, G. ; Szepeshazi, K. ; Cai, R. Z. ; Groot, K. ; Vadillo-Buenfil, M. ; Schally, Andrew V. / Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. In: European Journal of Cancer Part A. 1997 ; Vol. 33, No. 7. pp. 1141-1148.
@article{93436214ad134b9fb1e9ec2c20973b31,
title = "Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II",
abstract = "The aim of this study was to test the antagonist of LH-RH (Cetrorelix), agonist [D-Trp6]LH-RH (triptorelin) and new bombesin antagonists RC-3940-II and RC-3950-II for their effect on the growth of an androgen-independent prostate cancer cell line, DU-145, xenografted into nude mice. Xenografts were grown in male nude mice, and after 4 weeks, the animals were treated either with saline (control) or with one of the analogues. One group of mice was given a combination of Cetrorelix and RC-3950-II. Treatment was given for 4 weeks. Tumour and body weights, and tumour volumes were measured. At sacrifice, tumours were dissected for histological examination and receptor studies. Serum was collected for measurement of hormone levels. The final tumour volume in control animals injected with saline was 577 ± 155 mm3 and that of animals treated with Cetrorelix only 121.4 ± 45 mm3 (P < 0.01). Bombesin antagonists RC-3940-II and RC-3950-II also significantly reduced DU- 145 tumour volume in nude mice to 84.9 ± 19.9 and 96.8 ± 28 mm3 respectively. Agonist [D-Trp6]LH-RH did not significantly inhibit tumour growth. Serum levels of LH were decreased to 0.08 ± 0.02 ng/ml (P < 0.05) in the Cetrorelix treated group as compared to 1.02 ± 0.1 ng/ml for the controls, and testosterone levels were reduced to castration levels (0.01 ± 0.01 ng/ml). Specific receptors for EGF and LH-RH in DU-145 tumours were significantly downregulated after treatment with Cetrorelix, RC-3940-II and RC-3950-II. Although LH-RH could be a local regulator of growth of prostate cancer, the fall in LH-RH receptors is not fully understood and the inhibitory effects of Cetrorelix and bombesin antagonists on DU-145 tumour growth might be attributed at least in part to a downregulation of EHF receptors. Since Cetrorelix and bombesin antagonists inhibit growth of androgen-independent DU-145 prostate cancers, these compounds could be considered for the therapy of advanced prostate cancer in men, especially after relapse.",
keywords = "Androgen-independent prostate cancer, Bombesin/GRP antagonists, LH-RH antagonist",
author = "A. Jungwirth and J. Pinski and G. Galvan and G. Halmos and K. Szepeshazi and Cai, {R. Z.} and K. Groot and M. Vadillo-Buenfil and Schally, {Andrew V}",
year = "1997",
month = "6",
day = "1",
doi = "10.1016/S0959-8049(97)00072-5",
language = "English",
volume = "33",
pages = "1141--1148",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II

AU - Jungwirth, A.

AU - Pinski, J.

AU - Galvan, G.

AU - Halmos, G.

AU - Szepeshazi, K.

AU - Cai, R. Z.

AU - Groot, K.

AU - Vadillo-Buenfil, M.

AU - Schally, Andrew V

PY - 1997/6/1

Y1 - 1997/6/1

N2 - The aim of this study was to test the antagonist of LH-RH (Cetrorelix), agonist [D-Trp6]LH-RH (triptorelin) and new bombesin antagonists RC-3940-II and RC-3950-II for their effect on the growth of an androgen-independent prostate cancer cell line, DU-145, xenografted into nude mice. Xenografts were grown in male nude mice, and after 4 weeks, the animals were treated either with saline (control) or with one of the analogues. One group of mice was given a combination of Cetrorelix and RC-3950-II. Treatment was given for 4 weeks. Tumour and body weights, and tumour volumes were measured. At sacrifice, tumours were dissected for histological examination and receptor studies. Serum was collected for measurement of hormone levels. The final tumour volume in control animals injected with saline was 577 ± 155 mm3 and that of animals treated with Cetrorelix only 121.4 ± 45 mm3 (P < 0.01). Bombesin antagonists RC-3940-II and RC-3950-II also significantly reduced DU- 145 tumour volume in nude mice to 84.9 ± 19.9 and 96.8 ± 28 mm3 respectively. Agonist [D-Trp6]LH-RH did not significantly inhibit tumour growth. Serum levels of LH were decreased to 0.08 ± 0.02 ng/ml (P < 0.05) in the Cetrorelix treated group as compared to 1.02 ± 0.1 ng/ml for the controls, and testosterone levels were reduced to castration levels (0.01 ± 0.01 ng/ml). Specific receptors for EGF and LH-RH in DU-145 tumours were significantly downregulated after treatment with Cetrorelix, RC-3940-II and RC-3950-II. Although LH-RH could be a local regulator of growth of prostate cancer, the fall in LH-RH receptors is not fully understood and the inhibitory effects of Cetrorelix and bombesin antagonists on DU-145 tumour growth might be attributed at least in part to a downregulation of EHF receptors. Since Cetrorelix and bombesin antagonists inhibit growth of androgen-independent DU-145 prostate cancers, these compounds could be considered for the therapy of advanced prostate cancer in men, especially after relapse.

AB - The aim of this study was to test the antagonist of LH-RH (Cetrorelix), agonist [D-Trp6]LH-RH (triptorelin) and new bombesin antagonists RC-3940-II and RC-3950-II for their effect on the growth of an androgen-independent prostate cancer cell line, DU-145, xenografted into nude mice. Xenografts were grown in male nude mice, and after 4 weeks, the animals were treated either with saline (control) or with one of the analogues. One group of mice was given a combination of Cetrorelix and RC-3950-II. Treatment was given for 4 weeks. Tumour and body weights, and tumour volumes were measured. At sacrifice, tumours were dissected for histological examination and receptor studies. Serum was collected for measurement of hormone levels. The final tumour volume in control animals injected with saline was 577 ± 155 mm3 and that of animals treated with Cetrorelix only 121.4 ± 45 mm3 (P < 0.01). Bombesin antagonists RC-3940-II and RC-3950-II also significantly reduced DU- 145 tumour volume in nude mice to 84.9 ± 19.9 and 96.8 ± 28 mm3 respectively. Agonist [D-Trp6]LH-RH did not significantly inhibit tumour growth. Serum levels of LH were decreased to 0.08 ± 0.02 ng/ml (P < 0.05) in the Cetrorelix treated group as compared to 1.02 ± 0.1 ng/ml for the controls, and testosterone levels were reduced to castration levels (0.01 ± 0.01 ng/ml). Specific receptors for EGF and LH-RH in DU-145 tumours were significantly downregulated after treatment with Cetrorelix, RC-3940-II and RC-3950-II. Although LH-RH could be a local regulator of growth of prostate cancer, the fall in LH-RH receptors is not fully understood and the inhibitory effects of Cetrorelix and bombesin antagonists on DU-145 tumour growth might be attributed at least in part to a downregulation of EHF receptors. Since Cetrorelix and bombesin antagonists inhibit growth of androgen-independent DU-145 prostate cancers, these compounds could be considered for the therapy of advanced prostate cancer in men, especially after relapse.

KW - Androgen-independent prostate cancer

KW - Bombesin/GRP antagonists

KW - LH-RH antagonist

UR - http://www.scopus.com/inward/record.url?scp=0030814022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030814022&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(97)00072-5

DO - 10.1016/S0959-8049(97)00072-5

M3 - Article

C2 - 9376196

AN - SCOPUS:0030814022

VL - 33

SP - 1141

EP - 1148

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 7

ER -